Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 13/20 | 0.51 |
| ▸ | AR | P10275 | 2/20 | 0.46 |
| ▸ | BTK | Q06187 | 1/20 | 0.45 |
| ▸ | DDB1 | Q16531 | 9/20 | 0.44 |
| ▸ | MAP4K1 | Q92918 | 1/20 | 0.42 |
| ▸ | ALK | Q9UM73 | 2/20 | 0.39 |
| ▸ | GSPT1 | P15170 | 1/20 | 0.39 |
| ▸ | BRD9 | Q9H8M2 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28795420 | 0.98 | CRBN (0.49) | CRBNARBTKDDB1MAP4K1 | |
| SCHEMBL28795444 | 0.95 | CRBN (0.52) | CRBNARBTKDDB1MAP4K1 | |
| SCHEMBL28795225 | 0.94 | CRBN (0.53) | CRBNARBTKDDB1GSPT1 | |
| SCHEMBL28795226 | 0.93 | CRBN (0.52) | CRBNARBTKDDB1MAP4K1 | |
| SCHEMBL28795307 | 0.92 | CRBN (0.51) | CRBNARBTKDDB1MAP4K1 | |
| SCHEMBL28795151 | 0.89 | CRBN (0.57) | CRBNARBTKDDB1BRD9 | |
| SCHEMBL29803111 | 0.89 | CRBN (0.48) | CRBNARBTKDDB1MAP4K1 | |
| SCHEMBL28945689 | 0.89 | CRBN (0.48) | CRBNARBTKDDB1MAP4K1 | |
| SCHEMBL29803017 | 0.88 | CRBN (0.56) | CRBNARBTKDDB1BRD9 | |
| SCHEMBL28795113 | 0.88 | CRBN (0.56) | CRBNARBTKDDB1BRD9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114805303-A | Molecule with double functions of degrading EGFR (epidermal growth factor receptor), composition and pharmaceutical application thereof | 海思科医药集团股份有限公司 | 2022-07-29 | — | — | CN | disclosed |